Skip to content
OpenCapital
Get started

Bioventus BVS Enterprise value

Enterprise value at other companies

Stryker logo
StrykerSYK
$137.35B-12.4%
Zimmer Biomet Holdings logo
Zimmer Biomet HoldingsZBH
$24.74B-12.7%
Medtronic logo
MedtronicMDT
$131.22B-3.2%
SI-BONE, Inc. logo
SI-BONE, Inc.SIBN
$567.22M-4.1%
Artivion logo
ArtivionAORT
$1.96B+44.0%
Globus Medical logo
Globus MedicalGMED
$11.21B+15.6%

Other financials

Income statement

See full
Revenue$132.1M+6.6%
Gross profit$90.8M+9.3%
Operating income$8.4M+72.8%
Net income$3.1M+218%
EPS (diluted)$0.04+200%

Balance sheet

See full
Cash & equivalents$35.8M+57.2%
Total debt$288.4M-21.2%
Total equity$188.9M+27.5%
Total assets$650.5M-5.9%

Cash flow

See full
Operating cash flow$8.9M+146%
CapEx$574.0K-30.5%
Free cash flow$8.4M+141%

Valuation

See full
Market cap$659.19M+51.7%
P/E23.1×—
P/S1.1×+0.4×

Profitability

See full
Gross margin68.7%+1.2pp
Operating margin10%—
Net margin4.9%+3.2pp
FCF margin17.5%+13.2pp

Returns & leverage

See full
Return on equity16.9%+10.9pp
Debt / equity1.5×-0.9×
Current ratio1.7×+0.3×

Where this comes from

Calculated from Bioventus’s reported figures.

$615.1Mmarket cap+$288.4Mtotal debt−$35.8Mcash and equivalents=$867.64M

The official record: Bioventus’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Bioventus's enterprise value.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Bioventus's enterprise value?
Bioventus (BVS) reported enterprise value of $867.64M in Q1 2026.
How has Bioventus's enterprise value changed year-over-year?
Bioventus's enterprise value decreased by 8.5% year-over-year, from $948.66M to $867.64M.
What is the long-term trend for Bioventus's enterprise value?
Over 4 years (2021 to 2025), Bioventus's enterprise value has grown at a -10.0% compound annual growth rate (CAGR), from $1.15B to $758.41M.
What does enterprise value mean?
Market capitalization plus total debt minus cash, at the quarter end. The cost to acquire the whole business — what an buyer pays for equity and debt, net of the cash they'd inherit.